CytomX Therapeutics, Inc.
Hedge Funds Holdings
Last updated:
CytomX Therapeutics, Inc.‘s stocks are currently a part of 113 hedge funds’ portfolios, which represents 87.99% of the total amount of its stocks outstanding. This makes up a total of 53.64M shares of CytomX Therapeutics, Inc.. Compared to the previous quarter, the number fell by -1.71% or -933.90K shares fewer. As for the holding position changes, 29.2% (33) of current hedge fund investors increased the number of shares held, 35.4% (40) of current holders sold a part of the shares held, and 12.39% (14) closed the holdings completely. 21 hedge funds are new holders of CytomX Therapeutics, Inc. stock in Q1 2022, it is 18.58% of total holders.
Hedge funds holding CytomX Therapeutics (Q2 2017 – Q1 2022)
| Q2 2017 | 90 |
|---|---|
| Q3 2017 | 97 |
| Q4 2017 | 119 |
| Q1 2018 | 139 |
| Q2 2018 | 143 |
| Q3 2018 | 122 |
| Q4 2018 | 111 |
| Q1 2019 | 113 |
| Q2 2019 | 109 |
| Q3 2019 | 113 |
| Q4 2019 | 119 |
| Q1 2020 | 116 |
| Q2 2020 | 134 |
| Q3 2020 | 129 |
| Q4 2020 | 125 |
| Q1 2021 | 126 |
| Q2 2021 | 121 |
| Q3 2021 | 113 |
| Q4 2021 | 109 |
| Q1 2022 | 113 |
Hedge funds changes in CytomX Therapeutics positions (Q2 2017 – Q1 2022)
| Q2 2017 | 19 | 42 | 14 | 15 | 0 |
|---|---|---|---|---|---|
| Q3 2017 | 23 | 38 | 16 | 14 | 6 |
| Q4 2017 | 34 | 47 | 24 | 12 | 2 |
| Q1 2018 | 37 | 42 | 43 | 15 | 2 |
| Q2 2018 | 29 | 59 | 45 | 24 | -14 |
| Q3 2018 | 15 | 56 | 31 | 36 | -16 |
| Q4 2018 | 16 | 37 | 41 | 26 | -9 |
| Q1 2019 | 16 | 45 | 34 | 14 | 4 |
| Q2 2019 | 20 | 41 | 29 | 21 | -2 |
| Q3 2019 | 20 | 41 | 32 | 16 | 4 |
| Q4 2019 | 23 | 44 | 35 | 18 | -1 |
| Q1 2020 | 16 | 35 | 41 | 19 | 5 |
| Q2 2020 | 32 | 47 | 38 | 14 | 3 |
| Q3 2020 | 16 | 44 | 47 | 20 | 2 |
| Q4 2020 | 10 | 43 | 50 | 14 | 8 |
| Q1 2021 | 22 | 51 | 35 | 19 | -1 |
| Q2 2021 | 13 | 55 | 35 | 17 | 1 |
| Q3 2021 | 9 | 37 | 44 | 17 | 6 |
| Q4 2021 | 22 | 27 | 43 | 27 | -10 |
| Q1 2022 | 21 | 33 | 40 | 14 | 5 |
Hedge funds changes in CytomX Therapeutics stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 0 | 0 |
|---|---|---|
| Q3 2017 | 1,000 | 1,000 |
| Q4 2017 | 21,000 | 50,000 |
| Q1 2018 | 2,723,000 | 177,000 |
| Q2 2018 | 2,736,000 | 1,200,000 |
| Q3 2018 | 724,000 | 1,624,000 |
| Q4 2018 | 169,000 | 2,000 |
| Q1 2019 | 0 | 5,000 |
| Q2 2019 | 0 | 0 |
| Q3 2019 | 86,000 | 9,000 |
| Q4 2019 | 0 | 0 |
| Q1 2020 | 0 | 0 |
| Q2 2020 | 0 | 5,000 |
| Q3 2020 | 70,000 | 4,000 |
| Q4 2020 | 88,000 | 0 |
| Q1 2021 | 563,000 | 746,000 |
| Q2 2021 | 132,000 | 351,000 |
| Q3 2021 | 9,000 | 222,000 |
| Q4 2021 | 238,000 | 287,000 |
| Q1 2022 | 63,000 | 34,000 |